Chronic Heart Failure With Reduced Ejection Fraction
Conditions
Brief summary
Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization
Detailed description
Time to First Occurrence of CV Death, Time to First Occurrence of HF Hospitalization, Time to Total HF Hospitalizations (Including First and Recurrent Events), Time to First Occurrence of Composite Endpoint of All-Cause Mortality or HF Hospitalization, Time to All-Cause Mortality, Percentage of Participants who Experienced One or More Selected Nonserious Adverse Events (NSAE), Percentage of Participants Who Experienced One or More Serious Adverse Events (SAE), Percentage of Participants Who Experienced One or More Events of Clinical Interest (ECI)
Interventions
DRUGPlacebo to MK-1242 tablet 2.5 and 5 mg
DRUGPlacebo to MK-1242 tablet 10 mg
DRUGVericiguat
Sponsors
Merck Sharp & Dohme LLC
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to First Occurrence of CV Death, Time to First Occurrence of HF Hospitalization, Time to Total HF Hospitalizations (Including First and Recurrent Events), Time to First Occurrence of Composite Endpoint of All-Cause Mortality or HF Hospitalization, Time to All-Cause Mortality, Percentage of Participants who Experienced One or More Selected Nonserious Adverse Events (NSAE), Percentage of Participants Who Experienced One or More Serious Adverse Events (SAE), Percentage of Participants Who Experienced One or More Events of Clinical Interest (ECI) | — |
Countries
Austria, Czechia, Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Poland, Spain, Sweden
Outcome results
None listed